Multiple accumulated data suggest that blocking JAK-STAT signaling by irreversible Jakinib is potentially dangerous due to the risk of severe immunodeficiency; temporary and reversible JAK inhibition may provide safety and efficacy in treating many inflammatory conditions, including COVID-19 (Rommasi et al., 2022). Here, SOAT1 is linked to COVID-19.